COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Caffeine in Amblyopia Study (CAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02594358
Recruitment Status : Withdrawn (Could not recruit)
First Posted : November 3, 2015
Last Update Posted : March 7, 2017
Information provided by (Responsible Party):
Michael Repka, Johns Hopkins University

Brief Summary:

Prospective data on the visual acuity response in children treated by patching concurrently treated with caffeine and estimate the magnitude of effect that might be seen in a randomized trial (if no improvement in acuity is seen, this would be sufficient evidence to decide not to conduct a randomized, double blind trial).

Collect prospective data on the tolerability of caffeine in two dosages as an adjuvant treatment for amblyopia and provide limited data on its safety.

Evaluate the potential for a dietary intervention to enhance the acceptance and tolerability of patching on the child and family.

Demonstrate recruitment potential of subjects to participate in a dietary intervention study.

Condition or disease Intervention/treatment Phase
Amblyopia Drug: Caffeine Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : October 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amblyopia Caffeine

Arm Intervention/treatment
Active Comparator: Caffeine 20 mg
Patching plus once daily caffeine for 12 weeks
Drug: Caffeine

Active Comparator: Caffeine 40 mg
Patching plus once daily caffeine for 12 weeks
Drug: Caffeine

Primary Outcome Measures :
  1. Visual acuity [ Time Frame: 12 weeks ]
    Quantitative improvement in high resolution visual acuity measured at 3 meters

Secondary Outcome Measures :
  1. Questionnaire [ Time Frame: 12 weeks ]
    A multiquestion survey is adminsitered to the subjects specifically asking about side effects and quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   7 Years to 13 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Amblyopia from strabismus and amblyopia

Exclusion Criteria:

  • Known intolerance to caffeine
  • Diagnosis and/or treatment of attention deficit/hyperactivity disorder
  • Presence of an ocular cause for reduced visual acuity
  • Myopia with a special equivalent -6.00 diopters
  • Current vision therapy or orthoptics - any type
  • Ocular cause for reduced visual acuity
  • Prior intraocular or refractive surgery
  • History of narrow-angle glaucoma
  • Strabismus surgery planned within 16 weeks
  • Nystagmus per se does not exclude the subject if the above visual acuity criteria are met
  • Known skin reactions to patch or bandage adhesives
  • Known allergy or intolerance to food dyes
  • Current treatment with topical atropine eyedrops
  • Menarche, pregnancy or lactation
  • Use of any of the following medications which may affect caffeine metabolism: nafcillin, verapamil, fluvoxamine, ciprofloxacin and other fluoroquinolones, modafinil, nafcillin, and omeprazole

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02594358

Layout table for location information
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
Layout table for investigator information
Study Chair: Michael X Repka, MD, MBA Johns Hopkins University
Layout table for additonal information
Responsible Party: Michael Repka, Professor of Ophthalmology, Johns Hopkins University Identifier: NCT02594358    
Other Study ID Numbers: NA_00066787
First Posted: November 3, 2015    Key Record Dates
Last Update Posted: March 7, 2017
Last Verified: March 2017
Keywords provided by Michael Repka, Johns Hopkins University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Eye Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents